Avatrombopag 20mg is a prescription drug intended to raise platelet counts in people with particular medical disorders. It is marketed under the trade name Doptelet. It is commonly recommended to patients with thrombocytopenia (low platelet count) brought on by chronic liver disease (CLD) or chronic immunological thrombocytopenia (ITP). It is a member of the class of medications known as thrombopoietin receptor agonists (TPO-RAs).

This drug is a favorite among patients and medical experts due to its effectiveness, safety record, and ease of oral administration, which have earned it acclaim on a global scale.

Mechanism of Action

Avatrombopag increases platelet synthesis in the bone marrow by activating the thrombopoietin (TPO) receptor. Doptelet provides a focused and effective method of increasing platelet levels without producing undue adverse effects, in contrast to traditional platelet transfusions or older-generation TPO agonists.

Indications and Uses

Doptelet is FDA-approved and widely used in many countries for the following conditions:

1. Thrombocytopenia in Patients with Chronic Liver Disease (CLD)

• Low platelet counts are common in CLD patients, which raises the possibility of serious bleeding during medical treatments (such surgery or dental work).

• Avatrombopag lessens the need for platelet transfusions by raising platelet counts before to planned procedures.

2. Chronic Immune Thrombocytopenia (ITP)

• The autoimmune disease known as ITP causes the body to kill its own platelets, which can result in severe bleeding, life-threatening hemorrhages, and excessive bruising.

• Patients who have not responded well to immunoglobulin treatment or corticosteroids are prescribed doptelet.

3. Other Potential Uses (Off-label)

• Avatrombopag may help treat aplastic anemia or thrombocytopenia brought on by chemotherapy, according to some study, though these applications are still being studied.

Global Availability and Accessibility

Doptelet is extensively accessible in several areas, such as:

North America: Licensed by the U.S. Food and Drug Administration and used in the United States and Canada.

Europe: Used in a number of nations, including the UK, Germany, and France, and approved by the European Medicines Agency (EMA).

Asia & the Middle East: accessible through pharmacies and healthcare providers in China, India, Japan, the United Arab Emirates, and other areas.

With regulatory permissions pending, Latin America and Africa are becoming more accessible in important markets.

Dosage and Administration

The patient’s condition determines the Doptelet dosage: For CLD patients having surgery, the usual dosage is 40 mg (two 20 mg pills) every day for five days prior to the procedure.

The starting dose for ITP patients is 20 mg daily, with adjustments made in accordance to platelet response.

Note: Because incorrect use can result in difficulties, always abide by the doctor’s prescription.

Benefits of Avatrombopag (Doptelet)

Oral Tablet Form: Avatrombopag is a simple pill to swallow, as opposed to an injection or infusion.

Fewer Side Effects: Doptelet is less likely to cause bone marrow fibrosis and liver toxicity than previous TPO-RAs.

Decreased Bleeding Risk: It makes it safer for patients to get medical treatments without the need for platelet transfusions.

No Dietary Restrictions: Doptelet is not dependent on food, unlike Eltrombopag, which necessitates dietary changes.

Possible Side Effects

While generally well-tolerated, some patients may experience:
Headache
Fatigue
Nausea
Fever
Blood clot risks (in rare cases)

Seek medical help if you notice unusual swelling, severe headaches, or sudden shortness of breath, as these may indicate a serious reaction.

Precautions and Warnings

Not recommended for patients with active cancer or blood disorders unrelated to thrombocytopenia.

Monitor platelet levels regularly to avoid excessive clotting.

Not advised for pregnant or breastfeeding women without medical consultation.

Conclusion

Avatrombopag 20mg (Doptelet), a safe, practical, and efficient substitute for conventional treatments, has completely changed the way thrombocytopenia is treated globally. Because of its oral formulation, global availability, and excellent safety profile, it is the drug of choice for treating platelet shortages in patients with ITP and chronic liver disease.

Order Now At Mdx Pharma bd….

To order from MDX Pharma BD, visit their website at https://mdxpharmabd.com, where you can browse products and place orders online. For inquiries or orders via email, contact emedicarepharma@gmail.com. Alternatively, call (+88) 01929123476. Their address is 29, Abdullahpur, Uttara, Dhaka-1230, Bangladesh.

Q. What is one of liver cancer’s early warning signs?
Unintentional weight loss, appetite loss, upper abdominal pain, nausea, vomiting, general weakness and exhaustion, abdominal swelling, jaundice (yellowing of the eyes and skin), and white, chalky feces are some of the symptoms that may manifest when they do.

Q. What distinguishes avatrombopag from eltrombopag?
Another oral TPO-RA, avatrombopag (AVA), has been authorized to treat thrombocytopenia in adults with chronic liver disease. AVA is a suitable alternative for patients with abnormal liver function because it does not cause hepatotoxicity like ELT does.